UCB, Brussels, Belgium (www.ucb.com), established in 1928, is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders.
Employing more than 9,000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).
Main products are for the treatment of epilepsy, Parkinson disease, Crohn’s disease, Rheumatoid arthritis, Systemic Lupus Erythematosus.
RESEARCH & DEVELOPMENT
Investment in R&D (2009: €674 million).
A world leader in antibody research:
- SLAM technology to rapidly isolate functionally active antibodies
- Biological scaffolds to create more tolerable antibody-based therapies
- Pegylation to enhance the specificity and cost efficiency of biologics
- Unique and patented expertise in targeting the SV2A protein
- A large library of proprietary chemicals to unravel the role of SV2A in epilepsy and other diseases
2 Research Centres of Excellence:
- Braine-l’Alleud (Belgium) covering CNS disorders
- Slough (UK) covering oncology/immunology
Over thirty major R&D partnerships: includes Amgen (anti-sclerostin for bone loss disorders) .
An intellectual property estate of a large number of patent families.